William Blair Reduces Doximity Stake by $20.89 Million
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 09 2026
0mins
Should l Buy DOCS?
Source: Fool
- Share Reduction Details: According to a SEC filing dated February 9, 2026, William Blair reduced its Doximity stake by 372,184 shares during Q4 2025, with an estimated transaction value of $20.89 million, indicating a waning confidence in the company.
- Market Value and Performance Impact: The quarter-end value of Doximity's stake decreased by $184.77 million, primarily due to stock price declines and share sales, highlighting the company's poor market performance, particularly with its stock down 66% year-over-year.
- Investor Focus: Although this sale accounted for only 15% of William Blair's holdings, investors should closely monitor the firm's future stock strategy, especially as Doximity trades at its lowest valuation in history.
- Market Outlook Analysis: Despite a slowdown in sales growth to 10%, Doximity's potential in the pharmaceutical advertising market remains strong, with a full launch of AI applications expected in 2026, which could provide new growth momentum for the company.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy DOCS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on DOCS
Wall Street analysts forecast DOCS stock price to rise
18 Analyst Rating
14 Buy
4 Hold
0 Sell
Strong Buy
Current: 25.490
Low
25.00
Averages
42.75
High
63.00
Current: 25.490
Low
25.00
Averages
42.75
High
63.00
About DOCS
Doximity, Inc. provides a digital platform for the United States medical professionals. It offers marketing, hiring, and workflow solutions to pharmaceutical manufacturers, health systems, medical recruiting firms, and other healthcare companies. Its marketing solutions enable its pharmaceutical and health system customers to get the right content, services, and peer connections to the right medical professionals through a variety of modules. Its hiring solutions provide digital recruiting capabilities to health systems and medical recruiting firms, enabling them to identify, connect with, and hire from its network of both active and passive medical professional candidates, who might otherwise be missed through traditional recruiting channels. Its workflow solutions include its telehealth, on-call scheduling, and AI-powered workflow tools, are designed to help clinicians streamline their clinical workflow, reduce their administrative burden, and connect with patients and colleagues.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Analysis of DOCS Options Contracts and Investment Opportunities
- Put Option Appeal: The current bid for the $22.50 put option is $2.15, and if an investor sells this contract, they commit to buying shares at $22.50, resulting in a cost basis of $20.35, which is approximately a 10% discount from the current price of $24.95, making it attractive for those interested in DOCS.
- Yield Potential: Should the put option expire worthless, the premium would yield a 9.56% return on the cash commitment, or an annualized return of 12.28%, known as YieldBoost, highlighting the potential attractiveness of this investment strategy.
- Call Option Returns: The $30.00 call option has a current bid of $2.55, and if an investor buys DOCS shares at $24.95 and sells this call, they could achieve a total return of 30.46% if the stock is called away at expiration, showcasing the high return potential of this strategy.
- Risk Assessment: Current data indicates a 47% chance that the $30.00 call option may expire worthless, allowing investors to retain both their shares and the premium collected, further enhancing the safety and profitability of the investment.
See More
Doximity Stock Hits Low Amid AI Disruption Fears
- Market Reaction: Software stocks have been severely impacted by fears of AI disruption, with some stocks dropping 50% in just a few months, creating buying opportunities for high-quality businesses.
- Doximity Performance: Doximity's stock has fallen 66% over the past year and is trading near all-time lows, yet its underlying business remains strong, indicating robust competitiveness in the healthcare market.
- Revenue Growth: Doximity has experienced a phenomenal revenue increase of 448% since March 2020, although the latest quarter saw a slowdown to 10% year-over-year growth, suggesting significant potential within its existing medical marketing tools.
- Profitability: With an EBIT margin of 38.5%, Doximity stands out as best-in-class among software providers, and its price-to-earnings ratio of 21 indicates potential investment value amidst the current AI-induced market dip.
See More
Doximity Stock Declines Amid Software Stock Bust
- Market Performance: Doximity's stock has plummeted 66% during the 2026 software stock bust, trading near all-time lows despite strong profitability, indicating market concerns about its future prospects.
- Solid Customer Base: With 126 customers spending over $500,000 annually on the platform and 85% of U.S. physicians using it, Doximity demonstrates a strong lock on the medical social media market.
- Slowing Revenue Growth: Revenue has surged 448% since March 2020, but the latest quarter saw only 10% year-over-year growth, highlighting significant potential for further expansion within existing medical marketing tools.
- Strong Profitability: Doximity boasts a 38.5% EBIT margin, best-in-class for software providers, and trades at a price-to-earnings ratio of 21, positioning it as a potential growth stock for investors during the AI-fear dip.
See More
Investigation into Doximity Executives for Breach of Fiduciary Duties
- Legal Investigation Initiated: Halper Sadeh LLC is investigating whether certain Doximity Inc. executives breached their fiduciary duties to shareholders, which could impact corporate governance and shareholder rights.
- Shareholder Rights Protection: Long-term Doximity shareholders may seek corporate governance reforms, fund recovery, and court-approved financial incentives, aimed at enhancing company transparency and accountability.
- Legal Fee Arrangement: The firm will handle the case on a contingent fee basis, meaning shareholders will not incur out-of-pocket legal expenses, reducing the financial burden and encouraging broader participation.
- Improving Corporate Governance: Shareholder involvement can help enhance company policies and oversight mechanisms, thereby increasing shareholder value; Halper Sadeh LLC has extensive experience in driving corporate reforms and recovering funds.
See More
William Blair Reduces Doximity Stake by $20.89 Million
- Share Reduction Details: According to a SEC filing dated February 9, 2026, William Blair reduced its Doximity stake by 372,184 shares during Q4 2025, with an estimated transaction value of $20.89 million, indicating a waning confidence in the company.
- Market Value and Performance Impact: The quarter-end value of Doximity's stake decreased by $184.77 million, primarily due to stock price declines and share sales, highlighting the company's poor market performance, particularly with its stock down 66% year-over-year.
- Investor Focus: Although this sale accounted for only 15% of William Blair's holdings, investors should closely monitor the firm's future stock strategy, especially as Doximity trades at its lowest valuation in history.
- Market Outlook Analysis: Despite a slowdown in sales growth to 10%, Doximity's potential in the pharmaceutical advertising market remains strong, with a full launch of AI applications expected in 2026, which could provide new growth momentum for the company.
See More
William Blair Reduces Doximity Holdings
- Reduction in Holdings: William Blair sold 372,184 shares of Doximity in Q4 2025, with an estimated transaction value of $20.89 million, indicating a potential decline in confidence regarding the stock's future performance.
- Decline in Position Value: The quarter-end value of Doximity's holdings decreased by $184.77 million, reflecting both trading activities and stock price movements, suggesting a weakening market outlook for the company.
- Change in Asset Allocation: Post-sale, Doximity represented only 0.67% of William Blair's assets under management, indicating a diminished significance of the stock within the fund and potentially lowering investor interest.
- Poor Market Performance: As of February 6, 2026, Doximity shares were priced at $27.73, down 66% year-over-year and significantly underperforming the S&P 500, highlighting increasing competitive pressures in the healthcare information services sector.
See More
Analysis of DOCS Options Contracts and Investment Opportunities
- Put Option Appeal: The current bid for the $22.50 put option is $2.15, and if an investor sells this contract, they commit to buying shares at $22.50, resulting in a cost basis of $20.35, which is approximately a 10% discount from the current price of $24.95, making it attractive for those interested in DOCS.
- Yield Potential: Should the put option expire worthless, the premium would yield a 9.56% return on the cash commitment, or an annualized return of 12.28%, known as YieldBoost, highlighting the potential attractiveness of this investment strategy.
- Call Option Returns: The $30.00 call option has a current bid of $2.55, and if an investor buys DOCS shares at $24.95 and sells this call, they could achieve a total return of 30.46% if the stock is called away at expiration, showcasing the high return potential of this strategy.
- Risk Assessment: Current data indicates a 47% chance that the $30.00 call option may expire worthless, allowing investors to retain both their shares and the premium collected, further enhancing the safety and profitability of the investment.
See More
Doximity Stock Hits Low Amid AI Disruption Fears
- Market Reaction: Software stocks have been severely impacted by fears of AI disruption, with some stocks dropping 50% in just a few months, creating buying opportunities for high-quality businesses.
- Doximity Performance: Doximity's stock has fallen 66% over the past year and is trading near all-time lows, yet its underlying business remains strong, indicating robust competitiveness in the healthcare market.
- Revenue Growth: Doximity has experienced a phenomenal revenue increase of 448% since March 2020, although the latest quarter saw a slowdown to 10% year-over-year growth, suggesting significant potential within its existing medical marketing tools.
- Profitability: With an EBIT margin of 38.5%, Doximity stands out as best-in-class among software providers, and its price-to-earnings ratio of 21 indicates potential investment value amidst the current AI-induced market dip.
See More
Doximity Stock Declines Amid Software Stock Bust
- Market Performance: Doximity's stock has plummeted 66% during the 2026 software stock bust, trading near all-time lows despite strong profitability, indicating market concerns about its future prospects.
- Solid Customer Base: With 126 customers spending over $500,000 annually on the platform and 85% of U.S. physicians using it, Doximity demonstrates a strong lock on the medical social media market.
- Slowing Revenue Growth: Revenue has surged 448% since March 2020, but the latest quarter saw only 10% year-over-year growth, highlighting significant potential for further expansion within existing medical marketing tools.
- Strong Profitability: Doximity boasts a 38.5% EBIT margin, best-in-class for software providers, and trades at a price-to-earnings ratio of 21, positioning it as a potential growth stock for investors during the AI-fear dip.
See More
Investigation into Doximity Executives for Breach of Fiduciary Duties
- Legal Investigation Initiated: Halper Sadeh LLC is investigating whether certain Doximity Inc. executives breached their fiduciary duties to shareholders, which could impact corporate governance and shareholder rights.
- Shareholder Rights Protection: Long-term Doximity shareholders may seek corporate governance reforms, fund recovery, and court-approved financial incentives, aimed at enhancing company transparency and accountability.
- Legal Fee Arrangement: The firm will handle the case on a contingent fee basis, meaning shareholders will not incur out-of-pocket legal expenses, reducing the financial burden and encouraging broader participation.
- Improving Corporate Governance: Shareholder involvement can help enhance company policies and oversight mechanisms, thereby increasing shareholder value; Halper Sadeh LLC has extensive experience in driving corporate reforms and recovering funds.
See More
William Blair Reduces Doximity Stake by $20.89 Million
- Share Reduction Details: According to a SEC filing dated February 9, 2026, William Blair reduced its Doximity stake by 372,184 shares during Q4 2025, with an estimated transaction value of $20.89 million, indicating a waning confidence in the company.
- Market Value and Performance Impact: The quarter-end value of Doximity's stake decreased by $184.77 million, primarily due to stock price declines and share sales, highlighting the company's poor market performance, particularly with its stock down 66% year-over-year.
- Investor Focus: Although this sale accounted for only 15% of William Blair's holdings, investors should closely monitor the firm's future stock strategy, especially as Doximity trades at its lowest valuation in history.
- Market Outlook Analysis: Despite a slowdown in sales growth to 10%, Doximity's potential in the pharmaceutical advertising market remains strong, with a full launch of AI applications expected in 2026, which could provide new growth momentum for the company.
See More
William Blair Reduces Doximity Holdings
- Reduction in Holdings: William Blair sold 372,184 shares of Doximity in Q4 2025, with an estimated transaction value of $20.89 million, indicating a potential decline in confidence regarding the stock's future performance.
- Decline in Position Value: The quarter-end value of Doximity's holdings decreased by $184.77 million, reflecting both trading activities and stock price movements, suggesting a weakening market outlook for the company.
- Change in Asset Allocation: Post-sale, Doximity represented only 0.67% of William Blair's assets under management, indicating a diminished significance of the stock within the fund and potentially lowering investor interest.
- Poor Market Performance: As of February 6, 2026, Doximity shares were priced at $27.73, down 66% year-over-year and significantly underperforming the S&P 500, highlighting increasing competitive pressures in the healthcare information services sector.
See More
